Gland Pharma Reports 6% Revenue Growth in Q2 FY26 Results
Filing Summary
Gland Pharma Limited announced its Q2 FY26 financial results, reporting a 6% year-on-year increase in revenue, reaching ₹14,869 million. The company’s profit after tax (PAT) rose by 12% to ₹1,837 million. The USA and Europe markets showed significant growth, with revenues increasing by 10% and 16%, respectively. Research and development expenses were ₹614 million, representing 5.8% of revenue. The company launched seven new molecules in the USA and filed six ANDAs, with five approvals. An earnings call is scheduled for November 3, 2025, to discuss these results further.
Gland Pharma Limited has released its financial results for the second quarter of FY26, ending September 30, 2025. The company reported a 6% increase in revenue from operations, totaling ₹14,869 million compared to ₹14,058 million in the same quarter of the previous year. The profit after tax (PAT) for the quarter was ₹1,837 million, reflecting a 12% year-on-year growth. The results were disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The financial performance for the quarter included a gross profit of ₹9,331 million, up 12% from the previous year. The EBITDA stood at ₹3,139 million, marking a 6% increase year-on-year. The EBITDA margin remained consistent at 21%. The company’s adjusted EBITDA was ₹3,355 million, a 13% rise from the prior year, with an adjusted EBITDA margin of 23%. The profit before tax (PBT) was ₹2,839 million, an 11% increase year-on-year.
Operationally, Gland Pharma launched seven new molecules in the USA, including Daptomycin-RTU and Sumatriptan. The company filed six ANDAs and received five approvals during the quarter, contributing to a cumulative total of 378 ANDA filings in the U.S., with 329 approved and 49 pending. The company also reported an increase in R&D expenses to ₹614 million, accounting for 5.8% of revenue.
The timeline for the company’s strategic initiatives includes ongoing expansion in global CDMO capabilities and capacity enhancement in high-end modalities. The company is also focusing on its complex injectables pipeline, with six products already launched and three more awaiting approval. The company is increasing its GLP-1/Pen/cartridge capacity from approximately 40 million to 140 million units.
Gland Pharma’s market performance showed a 10% revenue increase in the USA and a 16% increase in Europe. The company’s operations in Canada, Australia, and New Zealand saw a 5% decline, while India experienced a 24% decrease. The rest of the world markets reported a 3% decline in revenue.
In the context of market relevance, Gland Pharma continues to focus on expanding its product portfolio and enhancing its manufacturing capabilities. The company’s strategic investments in R&D and new product launches aim to strengthen its position in the global pharmaceutical market. The company’s efforts in co-development partnerships and ready-to-use infusion bag products are part of its long-term growth strategy.
Gland Pharma Limited was established in 1978 in Hyderabad. It has evolved from a contract manufacturer to one of the largest injectable-focused companies globally, operating in over 60 countries. The company specializes in the development, manufacturing, and marketing of sterile injectables, including vials, ampoules, pre-filled syringes, and lyophilized vials. Gland Pharma operates primarily under a business-to-business model and has pioneered Heparin technology in India.